Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

ChemGenex Of Australia Seeks Funds To Develop First Drug In U.S.

This article was originally published in PharmAsia News

Executive Summary

Australia's ChemGenex Pharmaceuticals is attempting to raise funds to cover the cost of bringing its first drug to market, omacetaxine mepesuccinate for chronic myelogenous leukemia. The drug is intended for patients who no longer respond to drugs geared to treat the leukemia, and made by Novartis and Bristol-Myers Squibb. ChemGenex seeks to raise enough funding to allow it to apply for U.S. approval by mid-year. (Click here for more

Table

View full table

Tags:
Latest Headlines

Novartis Looks To Maintain A Lead In Radiopharmaceuticals With Mariana Takeout

Dupixent COPD Approval Could Be Delayed, Regeneron Cautions

Competition Forces Price Cuts, But Novo Nordisk Is Unstoppable

Metagenomi Looks For Upside To Moderna’s Exit

See All
UsernamePublicRestriction

Register

SC071559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By